Sansure Biotech Inc., (SHA: 688289), a leading molecular diagnostics company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its hepatitis B virus (HBV) RNA detection kit, which employs the PCR fluorescence probe method.
This advanced detection kit is designed for the quantitative detection of HBV RNA in clinical serum samples. The results provided by the kit can be utilized as a crucial auxiliary indicator to aid in the clinical diagnosis and treatment of individuals infected with hepatitis B. The kit boasts a detection sensitivity of 50 copies/mL and a linear range from 1.0E+02 copies/mL to 1.0E+09 copies/mL, making it a versatile tool suitable for various medical institutions and clinical settings.- Flcube.com
